Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations.

Oxman, Michael N; Schmader, Kenneth E

Oxman, Michael N; Schmader, Kenneth E.

Oxman MN; Infectious Diseases Section, Medicine Service, Veterans Affairs San Diego Healthcare System Division of Infectious Diseases, University of California San Diego School of Medicine.
Schmader KE; Geriatric Research, Education and Clinical Center, Durham Veterans Affairs Medical Center Department of Medicine, Duke University, Durham, North Carolina.

Clin Infect Dis ; 59(7): 920-2, 2014 Oct.

Article en En | MEDLINE | ID: mdl-25097080

Asunto(s)

Antineoplásicos/uso terapéutico; Vacuna contra el Herpes Zóster/administración & dosificación; Vacuna contra el Herpes Zóster/inmunología; Herpes Zóster/epidemiología; Herpes Zóster/prevención & control; Neoplasias/complicaciones; Femenino; Humanos; Masculino

Palabras clave

cancer chemotherapy; herpes zoster; immunization; varicella-zoster virus; zoster vaccine

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacuna contra el Herpes Zóster / Herpes Zóster / Neoplasias / Antineoplásicos Límite: Female / Humans / Male Idioma: En Año: 2014 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google